Aducanumab: European agency rejects Alzheimer's drug over efficacy and safety concerns
BMJ
.
2021 Dec 20:375:n3127.
doi: 10.1136/bmj.n3127.
Author
Elisabeth Mahase
1
Affiliation
1
The BMJ.
PMID:
34930757
DOI:
10.1136/bmj.n3127
No abstract available